证券代码：688513 证券简称：苑东生物 公告编号：2025-049 成都苑东生物制药股份有限公司 关于自愿披露盐酸麻黄碱注射液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，现将相关 情况公告如下： 上市许可持有人：成都苑东生物制药股份有限公司 生产企业：成都苑东生物制药股份有限公司 药品注册标准编号：YBH14452025 受理号：CYHS2400825 证书编号：2025S02157 药品批准文号：国药准字 H20254836 一、药品基本情况 药品名称：盐酸麻黄碱注射液 剂型：注射剂 规格：5ml:23.5mg 注册分类：化学药品 3 类 药品有效期：18 个月 审批结论： 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及 1 生产工艺照所附执行。药品生产企业应当符合药品生产 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Ephedrine Hydrochloride Injection, marking a significant milestone as the first domestic company to obtain this approval under the new classification system [1] Group 1: Product Development - Ephedrine Hydrochloride Injection is developed by Eton Pharmaceuticals, Inc. and was approved by the FDA in June 2021 under the brand name Rezipres [1] - The product is indicated for the treatment of clinically significant hypotension occurring during anesthesia [1] Group 2: Market Impact - The projected sales revenue for Ephedrine Hydrochloride Injection in 2024 is approximately 109 million yuan, reflecting a year-on-year growth of 14.35% [1]

Group 1 - The company Chengdu Yuandong Biopharmaceutical Co., Ltd. is convening its first extraordinary general meeting of shareholders in 2025 on August 1, 2025, at 14:00 [1][2] - The voting method for the meeting will combine on-site voting and online voting through the Shanghai Stock Exchange network voting system [1][2] - The meeting will review proposals that have been approved by the company's fourth board of directors during its sixth meeting [2][3] Group 2 - Shareholders can vote through the Shanghai Stock Exchange network voting system, with specific voting times outlined for both trading and internet platforms [1][3] - The company will provide a reminder service for shareholders to participate in the meeting and vote, utilizing smart SMS notifications [3][5] - The registration for attending the meeting requires specific identification and documentation, with a deadline for submission set for July 29, 2025 [5][6] Group 3 - The meeting will include voting on non-cumulative proposals, including the removal of an independent director and the election of a new independent director [7][8] - Shareholders must complete voting on all proposals before submitting their votes [3][4] - The company will not accept telephone registrations for the meeting, emphasizing the need for physical or electronic submission of required documents [5][6]

Core Viewpoint - The nomination of Li Weifeng as an independent director candidate for Chengdu Yuandong Pharmaceutical Co., Ltd. has been made by the controlling shareholder Wang Ying, who asserts that the candidate meets all necessary qualifications and independence criteria [1][5]. Summary by Relevant Sections Nomination and Qualifications - Wang Ying, the controlling shareholder, has nominated Li Weifeng as an independent director candidate for the fourth board of Chengdu Yuandong Pharmaceutical Co., Ltd. The nominee has agreed to the position and possesses the required professional knowledge and experience [1]. - The nominee has over 5 years of relevant work experience in law, economics, accounting, finance, or management, and has completed the necessary training for independent directors [1]. Compliance with Regulations - The nominee's qualifications comply with various legal and regulatory requirements, including the Company Law of the People's Republic of China and the regulations set forth by the China Securities Regulatory Commission [1]. - Specific regulations regarding the independence of directors have been adhered to, ensuring that the nominee does not fall under any disqualifying conditions [2][3]. Independence Criteria - The nominee is confirmed to be independent, not holding any significant shares or positions that could compromise their impartiality [2][3]. - The nominee has no adverse records, such as administrative or criminal penalties from the China Securities Regulatory Commission in the last 36 months [4]. Additional Information - The nominee has not served as an independent director in more than three domestic listed companies and has not held the position in Chengdu Yuandong Pharmaceutical Co., Ltd. for more than six years [4]. - The nomination has passed the qualification review by the board's nomination committee, confirming no conflicts of interest exist between the nominator and the nominee [4].

独立董事候选人声明与承诺 本人李卫锋，已充分了解并同意由提名人成都苑东生物制药 股份有限公司控股股东、实际控制人王颖 提名为成都苑东生物 制药股份有限公司第四届董事会独立董事候选人。本人公开声明， 本人具备独立董事任职资格，保证不存在任何影响本人担任成都 苑东生物制药股份有限公司独立董事独立性的关系，具体声明并 承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验， 并已根据《上市公司高级管理人员培训工作指引》及相关规定完 成了独立董事履职学习，具备独立董事任职资格。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定（不适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退（离）休后担任上市公 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-047 成都苑东生物制药股份有限公司 关于变更独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于 2025 年 7 月 16 日 召开了第四届董事会第六次会议，审议通过了《关于免去彭龙先生独立董事职 务的议案》、《关于补选公司第四届董事会独立董事的议案》，现将具体内容公告 如下： 一、变更独立董事情况 董事会 2025 年 7 月 17 日 2 鉴于公司独立董事彭龙先生因个人原因目前正在接受纪律审查和监察调查， 无法正常履职，为保证公司董事会的正常运作，根据《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》《上市公司独立董事管理办法》以 及《公司章程》等相关规定，董事会决定免去彭龙先生的独立董事职务及其在 董事会各专门委员会中担任的全部职务，免职后，彭龙先生将不再担任公司任 何职务。彭龙先生独立董事职务免职事项自公司股东大会审议通过之日起生效。 鉴于公司免去彭龙先生独立董事的职务 ...

（二）《中华人民共和国公务员法》关于公务员兼任职务的 规定（不适用）； 独立董事提名人声明与承诺 提名人成都苑东生物制药股份有限公司控股股东、实际控制 人王颖，现提名李卫锋为成都苑东生物制药股份有限公司第四届 董事会独立董事候选人，并已充分了解被提名人职业、学历、职 称、详细的工作经历、全部兼职、有无重大失信等不良记录等情 况。被提名人已同意出任成都苑东生物制药股份有限公司第四届 董事会独立董事候选人（参见该独立董事候选人声明）。提名人 认为，被提名人具备独立董事任职资格，与成都苑东生物制药股 份有限公司之间不存在任何影响其独立性的关系，具体声明并承 诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验， 并已根据《上市公司高级管理人员培训工作指引》及相关规定完 成了独立董事履职学习，具备独立董事任职资格。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （三）中国证监会《上市公司独立董事管理办法》、上海证 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-048 成都苑东生物制药股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 （二） 股东大会召集人：董事会 至2025 年 8 月 1 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 股东大会召开日期：2025年8月1日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 8 月 1 ...

二、董事会会议审议情况 经与会董事审议，逐项表决，形成决议如下： 证券代码：688513 证券简称：苑东生物 公告编号：2025-046 成都苑东生物制药股份有限公司 第四届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都苑东生物制药股份有限公司（以下称"公司"）第四届董事会第六次会议 于 2025 年 7 月 16 日以现场和通讯相结合的方式召开。会议通知已于 2025 年 7 月 14 日以专人送达、电话通知、电子邮件等形式临时送达全体董事。本次会议 由董事长王颖女士主持，应出席董事 9 名，实际出席董事 8 名，独立董事彭龙先 生因正在接受纪律审查和监察调查未参加会议。本次会议的召集、召开和表决程 序符合《中华人民共和国公司法》等相关法规和《成都苑东生物制药股份有限公 司章程》的规定，会议形成的决议合法有效。 （一）审议通过《关于免去彭龙先生独立董事职务的议案》 （二）审议通过《关于补选公司第四届董事会独立董事的议案》 本议案已经董事会提名委员会审议通过。 鉴于公 ...

Group 1 - Shengde Xintai won a bid for a thermal power steel pipe project worth approximately 217 million yuan, accounting for 8.15% of its audited revenue for 2024 [1] - High-speed Electric's subsidiary won a project for the Shanghai-Nanjing-Hefei high-speed railway, with a bid amount of 71.76 million yuan [1] - Cangge Mining's subsidiary received a construction permit for a lithium-boron mining project, with a construction area of 106,900 square meters [2] Group 2 - China Electric Power Construction signed a mining transportation project contract in Guinea worth approximately 5.063 billion yuan, with a total duration of about 72 months [3] - Guobang Pharmaceutical's subsidiary completed the registration of an equity investment fund focusing on strategic emerging industries [4] - Deshi Co. obtained two invention patents related to oil and gas field development [5][26] Group 3 - Xue Tian Salt Industry expects a significant decrease in net profit for the first half of 2025, projecting a decline of 76.34% to 80.29% [6] - Rundu Co. received a drug registration certificate for moxifloxacin hydrochloride tablets, used for treating various bacterial infections [7] - China Nuclear Power reported a 15.65% increase in power generation in the first half of the year, with nuclear power generation up by 12.01% [8] Group 4 - Suqian Liansheng obtained two invention patents related to wastewater treatment methods [9] - Boshi Co. signed a 109 million yuan operation and maintenance service contract for solid product packaging [11] - *ST Sailong's subsidiary received a drug registration certificate for torasemide injection, used for various medical conditions [13] Group 5 - North Bay Port reported a 10.95% increase in cargo throughput for the first half of 2025, with container throughput also showing growth [14] - Kaiwei Te expects a revenue increase of 56.17% to 90.87% for the first half of 2025 [15] - Wankai New Materials plans to reduce production and conduct maintenance on 60,000 tons of PET capacity, affecting overall performance [16] Group 6 - Haiwang Bio's HW130 injection successfully completed Phase I clinical trials, showing good safety and tolerability [19] - Zhenai Meijia received a total of 22.8 million yuan in compensation for land acquisition, which will significantly impact its 2025 performance [20] - Changyuan Electric reported a 23.58% decrease in power generation in June, with a notable decline in thermal power generation [21] Group 7 - Shouxiangu's subsidiary completed the registration of two health food products [22] - Kailun Co. announced the resignation of its deputy general manager and board secretary [23] - Xibu Muye reported a 2.15% year-on-year increase in fresh milk production in June [24] Group 8 - Deshi Co. obtained two invention patents related to oil and gas field development [26] - Jingwei Huikai plans to acquire a 12.44% stake in Nuo Si Micro for 149 million yuan [27] - Electric Alloy completed the registration of its subsidiary in Mexico [29] Group 9 - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of 2025 [30] - Guizhou Moutai repurchased approximately 3.38 million shares, accounting for 0.2692% of its total share capital [31][32] - Warner Pharmaceutical received approval for the listing application of a raw material drug for treating respiratory diseases [34] Group 10 - Yuan Dong Bio's independent director is under investigation for serious violations [35] - Dash Intelligent signed a contract for a smart project worth 11.88 million yuan [36] - Dayou Energy plans to transfer 586,500 tons of coal production capacity replacement indicators [37] Group 11 - Foton Motor reported a 150.96% increase in new energy vehicle sales in the first half of 2025 [39] - Renfu Pharmaceutical's shareholder plans to increase its stake by 1% to 2% [40] - Zongshen Power expects a net profit increase of 70% to 100% for the first half of 2025 [42] Group 12 - Yingboer plans to sell its wholly-owned subsidiary for 239 million yuan [44] - Changan Automobile reported a 1.59% increase in total vehicle sales in the first half of 2025 [46] - Fulian Precision signed a cooperation framework agreement with Sichuan Development Longmang [48] Group 13 - Nengte Technology plans to repurchase shares worth 300 million to 500 million yuan [50] - Longsoft Technology's controlling shareholder donated 3.43% of the company's shares [51] - Data Port's shareholders plan to reduce their holdings by up to 2% [52]